Table 1 Key information of the DAPA-MI trial [38]

Class &

Cardiovascular (CV) outcomes

WR (95% CI)

p-value‡

Primary outcome

Composite of death, HHF, nonfatal MI, AF/flutter, T2D, NYHA class, body weight decrease ≥ 5%

1.34 (1.20 to 1.50)

< 0.001

Key secondary outcome

Composite of death, HHF, nonfatal MI, AF/flutter, T2D, NYHA class

1.20 (1.04 to 1.40)

0.015

Other secondary endpoints

HR (95% CI)

Composite of CV death/HHF

0.95 (0.64 to 1.40)

CV death/HHF/MI

0.95 (0.70 to 1.29)

MACE (MI, stroke, or CV death)

0.94 (0.67 to 1.31)

All-cause death

1.22 (0.77 to 1.92)

CV death

1.15 (0.66 to 2.01)

MI

1.11 (0.72 to 1.71)

Stroke

0.61 (0.28 to 1.34)

New diagnosis of T2D

0.53 (0.36 to 0.77)

New diagnosis of AF/flutter

0.88 (0.45 to 1.73)

All-cause hospitalization

1.12 (0.97 to 1.29)

Adjudicated HHF

0.83 (0.50 to 1.39)